M&A activity and investor cash expected to re-invigorate pharma and biotech in 2018

6 Dec 2017

Public and private investors look set to remain supportive of innovative, early-stage drug developers.

The upward momentum seen in the pharma and biotech sectors during 2017 looks set to continue into 2018, with more novel medicines due to hit the market and investor support for the industry remaining strong. According to EP Vantage, the current business-friendly stance at the FDA is unlikely to change next year, and M&A could see an uptick, driven by Big Pharma and big biotech’s need to re-stock pipelines and US tax reforms.

M&A activity and investor cash expected to re-invigorate pharma and biotech in 2018

The coming year will also test the commercial expectations that have been hung on novel therapies such as CAR-T and gene therapy, which are being launched into increasingly cost-sensitive markets. Important clinical read-outs from the field of immuno-oncology, where asset values remain very high, will be closely watched - all of which will help set the tone for investors throughout the year.

“Venture capital funds are very well stocked going into 2018, and both public and private investors look set to remain supportive of innovative, early-stage drug developers,” says Amy Brown, report author. “However there is evidence that expectations have got ahead of themselves in certain areas – particularly in immuno-oncology. To keep investors on side next year the industry needs to deliver some big pipeline wins, and important new drug launches need to perform.”

“Pharma & Biotech 2018 Preview”- Analysis Highlights:

  • Gilead’s new HIV triplet is the biggest potential new drug launch of 2018, with 2022 sales seen reaching $5bn
  • Abbvie’s Humira will be biggest selling drug in 2018, with global sales topping $20bn
  • Merck’s Keytruda will add the most new sales next year, $2.3bn
  • M&A activity expected to climb after slow 2017 – US tax reform could be a deciding factor for big deals
  • Another big year predicted for venture financing, as crossover funds return and push 2017 towards a record
  • IPO window expected to remain open to cashed-up private companies
  • Another strong year expected for licensing transactions in 2018, with a pick-up in activity in 2017 set to continue
  • Focus on immuno-oncology set to continue with new checkpoint targets moving through the clinic
  • Drug pricing debate in US expected to ease, but keep an eye on the states
  • Read More

    Related tags

    Market News

    Related news

    BIA Separations expands with new upstream processing facility

    BIA Separations expands with new upstream processing facility

    20 Sep 2018

    Provides single source of expertise for scaled production of complex biologics for gene therapy and vaccines.

    Read more 
    Sanofi to refocus two global business units

    Sanofi to refocus two global business units

    19 Sep 2018

    The new Primary Care and China & Emerging Markets global business units are expected to launch at the beginning of 2019.

    Read more 
    Experts warn trade and patent changes could increase healthcare cost by $100bn over next 5 years

    Experts warn trade and patent changes could increase healthcare cost by $100bn over next 5 years

    18 Sep 2018

    China is harmonizing to ICH standards at feverish pace and will force poor quality manufacturers out of market.

    Read more 
    Recipharm connects to European Hub for serialisation compliance

    Recipharm connects to European Hub for serialisation compliance

    18 Sep 2018

    Connection allows the marketing authorisation holders within the Recipharm Group to continue to supply medicines to patients post the EU FMD implementation date.

    Read more 
    Bosch to unveil new laboratory device for continuous manufacturing

    Bosch to unveil new laboratory device for continuous manufacturing

    18 Sep 2018

    The Xelum R&D offers pharmaceutical manufacturers an ideal start to continuous OSD production.

    Read more 
    Partnership to deliver integrated, off-the-shelf biosimilar manufacturing solutions

    Partnership to deliver integrated, off-the-shelf biosimilar manufacturing solutions

    17 Sep 2018

    Pall and Aetos to advance the market impact of biosimilars and deliver lower-priced, high-quality options to end users.

    Read more 
    Cambrex expands manufacturing footprint with acquisition

    Cambrex expands manufacturing footprint with acquisition

    16 Sep 2018

    Completed acquisition adds formulation development and finished dosage manufacturing capabilities to Cambrex’s existing global API manufacturing network.

    Read more 
    NMPA approves fruquintinib capsules for metastatic colorectal cancer

    NMPA approves fruquintinib capsules for metastatic colorectal cancer

    13 Sep 2018

    Fruquintinib - innovative medicine that has not previously been launched in China or internationally - provides a new therapeutic approach for metastatic colorectal cancer patients.

    Read more 
    Aptar Pharma to showcase an industry first

    Aptar Pharma to showcase an industry first

    12 Sep 2018

    PureHale is a new portable drug delivery device designed for upper respiratory care.

    Read more 
    Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio

    Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio

    11 Sep 2018

    The Sandoz US portfolios to be sold to Aurobindo include approximately 300 products, as well as additional development projects.

    Read more